Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase – Still a Buy?

Pharming Group (NASDAQ:PHAR) shares saw an uptick in trading volume on Tuesday . 5,484 shares traded hands during mid-day trading, an increase of 7% from the previous session’s volume of 5,115 shares.The stock last traded at $8.83 and had previously closed at $8.78.

Analysts Set New Price Targets

PHAR has been the topic of several analyst reports. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock. Oppenheimer lowered their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Trading Up 0.8 %

The business’s 50-day moving average price is $9.23 and its 200 day moving average price is $8.43. The firm has a market capitalization of $601.45 million, a price-to-earnings ratio of -34.00 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.